ReviewF1000Research2018
Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- Pooled it
- Interaction between intestinal microbiota, inflammatory cytokines, and the expression of miR-330-3p and miR-515-5p in patients with ulcerative colitis.Journal of medical biochemistry · 2026Article
- The mechanism of indigo naturalis and its active ingredients against ulcerative colitis.Scientific reports · 2026Article
- Anti-inflammatory activity of collagen peptide in vitro and its effect on improving ulcerative colitis.NPJ science of food · 2025Article
- Integrative biomarker discovery and immune profiling for ulcerative colitis: a multi-methodological approach.Scientific reports · 2024Article
- Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis.World journal of clinical cases · 2024Article
- The emerging roles of circHECTD1 in human diseases and the specific underlying regulatory mechanisms.PeerJ · 2024Review
- Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis.Nature communications · 2023Article
- Medicinal Plants, Phytochemicals and Regulation of the NLRP3 Inflammasome in Inflammatory Bowel Diseases: A Comprehensive Review.Metabolites · 2023Review
- Beneficial Effects of Hordenine on a Model of Ulcerative Colitis.Molecules (Basel, Switzerland) · 2023Article
- Kimchi andFoods (Basel, Switzerland) · 2023Article
- Ileo-Anal Pouch Anastomosis and New Remedial Approaches for Ulcerative Colitis: A Review Article.Cureus · 2023Review
- Significance of diagnosis and prognosis for appendiceal orifice inflammation in ulcerative colitis: a real-world study.BMJ open · 2022Observational
- Effect of fecal microbiota transplantation on the TGF-β1/Smad signaling pathway in rats with TNBS-induced colitis.Annals of translational medicine · 2022Article
- Efficacy of Sishen Wan on dinitrobenzene sulfonic acid-induced ulcerative colitis and its effect on toll-like receptor 2/interleukin-1 receptor-associated kinase-4/nuclear factor-κB signal pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-κB.Annals of translational medicine · 2022Article
- Cell division control 42 elevates during infliximab therapy, and its increment relates to treatment response in ulcerative colitis patients.Journal of clinical laboratory analysis · 2022Article
- Natural Products Modulate Cell Apoptosis: A Promising Way for the Treatment of Ulcerative Colitis.Frontiers in pharmacology · 2022Review
- Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.Inflammatory intestinal diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The so-called "biologicals" (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug's role in future treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.